Solid-variant primary pulmonary adenoid cystic carcinoma with pleural metastasis and malignant pleural effusion: a rare case report - Takeaways - MDSpire

Solid-variant primary pulmonary adenoid cystic carcinoma with pleural metastasis and malignant pleural effusion: a rare case report

  • By

  • Suyi Guo

  • Yang Zhai

  • Hongbian Gao

  • Caixia Ding

  • May 18, 2026

Share

  • 1

    Primary pulmonary adenoid cystic carcinoma (PACC) is a rare lung malignancy, constituting 0.04%–0.2% of primary lung neoplasms.

  • 2

    The solid variant of PACC is characterized by aggressive behavior and poses significant diagnostic challenges due to its immunophenotypic overlap with squamous cell carcinoma.

  • 3

    A 65-year-old man was diagnosed with solid-variant PACC after initial misinterpretation as squamous cell carcinoma, highlighting diagnostic pitfalls.

  • 4

    The patient presented with pleural metastasis and malignant pleural effusion, classified as stage IV disease, receiving a combination of immunotherapy and chemotherapy.

  • 5

    This case provides preliminary evidence for the feasibility of chemoimmunotherapy in advanced PACC, emphasizing the need for accurate diagnostic approaches.

Original Source(s)

Solid-variant primary pulmonary adenoid cystic carcinoma with pleural metastasis and malignant pleural effusion: a rare case report

  • by Suyi Guo, Yang Zhai, Hongbian Gao, Caixia Ding

  • May 18, 2026

Related Content

Neoadjuvant Single-Cycle Pembrolizumab for Stage I to III dMMR Colon Cancer

In a Danish phase II trial (RESET-C) reported in the Journal of Clinical Oncology, Gögenur et al found that a single cycle of neoadjuvant pembrolizumab was associated with pathologic complete response...

Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age

Investigators have found that overdiagnosis of prostate cancer through prostate-specific antigen screening is low in younger men—but rises sharply with age.

FDA Approves Fam-Trastuzumab Deruxtecan-nxki Indications in HER2-Positive Early Breast Cancer

On May 15, 2026, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu) for two separate indications for the treatment of adult patients with HER2-positive earl...